Effects of the Fluoroquinolone Antibacterial Drug Ciprofloxacin on Ventricular Repolarization in the Halothane-Anesthetized Guinea Pig

• Matsuo Kazuhiro

  Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Japan

• Fujiwara Kaori

  Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University, Japan

• Omuro Naoki

  Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University, Japan

• Kimura Itsuki

  Department of Pharmacy, Toho University Omori Medical Center, Japan

• Kobayashi Kazuko

  Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University, Japan

• Yoshio Takashi

  Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Japan

• Takahara Akira

  Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University, Japan

抄録

The fluoroquinolone antibiotic ciprofloxacin has been reported to block delayed rectifier K⁺ channels at much higher concentrations than those at which it exerts its bactericidal activity. In this study using the halothane-anesthetized guinea pig, we assessed whether ciprofloxacin has a proarrhythmic activity. Ciprofloxacin at a clinically relevant dose of 3 mg/kg, i.v. did not affect any electrocardiographic parameters. At 10 mg/kg, it prolonged the QT interval and the duration of the monophasic action potential of the ventricle under sinus rhythm and constant ventricular pacing (n = 6). The extents of its effects on the ventricular repolarization phase were comparable to those of another fluoroquinolone antibiotic moxifloxacin at a clinically relevant dose of 3 mg/kg (n = 6). Meanwhile, the PR interval and QRS width were also increased by ciprofloxacin at 10 mg/kg, suggesting that the drug inhibited cardiac K⁺ channels as well as Na⁺ and Ca²⁺ channels in vivo. These results suggest that ciprofloxacin exerted a multi-ion channel–blocking action in the heart within the supra-therapeutic dose range. Therefore, careful observation may be necessary for patients with heart disease receiving a higher dose of ciprofloxacin in order to prevent the emergence of resistance.

収録刊行物

• Journal of Pharmacological Sciences

  Journal of Pharmacological Sciences 122 (3), 205-212, 2013

  公益社団法人 日本薬理学会

キーワード

• ciprofloxacin
• fluoroquinolone antibiotic
• QT interval
• monophasic action potential

詳細情報

• CRID: 1390001205180389760
• NII論文ID: 10031185414
• NII書誌ID: AA11806667
• DOI: 10.1254/jphs.13020fp
• COI: 1:CAS:528:DC%2BC3sXht12hu7zK
• ISSN: 13478648
• ISSN: 13478613
• NDL書誌ID: 024706024
• PubMed: 23803533
• Web Site: http://id.ndl.go.jp/bib/024706024
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I024706024
• Web Site: https://www.jstage.jst.go.jp/article/jphs/122/3/122_13020FP/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2014059688
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可